| 股票 | 标签 | 申万二级 | PE | 前瞻PE | PEG | PB | 股息率 | 分红率 | 毛利率 | 固定资产 | 债/EBITDA | FCF/市值 | 营收3年 | 去年 | YTD | 近一年 | 回撤 | 波动 | 市值亿 ▾ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 药明康德 603259 | 成长兑现 | 医疗服务 | 21.3 | 20.8 | 0.95 | 5.55 | 1.4% | 60% | 41% | 24% | 0.6 | 2.8% | +5% | +73% | +74% | +58% | -23% | 45% | 4622 |
| 爱尔眼科 300015 | 定价权·品牌 | 医疗服务 | 30.6 | 22.1 | 1.10 | 3.39 | 2.1% | 42% | 50% | 19% | 1.1 | 4.7% | +12% | -16% | -22% | -38% | -42% | 28% | 780 |
| 康龙化成 300759 | 中性 | 医疗服务 | 44.2 | 37.6 | 1.39 | 4.63 | 0.5% | 21% | 36% | 41% | 1.9 | 0.0% | +11% | +12% | +46% | +30% | -40% | 48% | 757 |
| 凯莱英 002821 | 中性 | 医疗服务 | 56.8 | 42.1 | 1.45 | 3.31 | 0.8% | 41% | 44% | 32% | 0.2 | -0.2% | -13% | +24% | +78% | +49% | -25% | 54% | 588 |
| 百奥赛图 688796 | 亏损或困境 | 医疗服务 | 146.3 | 133.4 | 2.38 | 22.12 | — | — | 73% | 33% | 1.4 | 0.3% | +37% | — | +128% | — | -25% | 82% | 536 |
| 泰格医药 300347 | 纯久期 | 医疗服务 | 471.1 | 49.8 | 0.94 | 2.21 | 0.2% | 24% | 39% | 4% | 2.1 | 2.1% | -1% | +4% | -12% | -27% | -46% | 48% | 431 |
| 昭衍新药 603127 | 中性 | 医疗服务 | 32.7 | 51.1 | — | 3.59 | 0.3% | 30% | 43% | 10% | 0.3 | 0.9% | -10% | +112% | +23% | +31% | -38% | 66% | 322 |
| 皓元医药 688131 | 纯久期 | 医疗服务 | 73.1 | 55.5 | 1.35 | 5.88 | 0.3% | 20% | 48% | 18% | 3.5 | 1.0% | +28% | +104% | +24% | +42% | -32% | 60% | 189 |
| 美年健康 002044 | 轻资产现金牛 | 医疗服务 | 55.6 | 42.9 | 1.87 | 2.27 | 0.2% | 15% | 41% | 8% | 2.7 | 7.7% | +7% | +15% | -12% | -20% | -49% | 51% | 180 |
| 通策医疗 600763 | 中性 | 医疗服务 | 25.7 | 26.4 | 2.03 | 3.82 | — | 48% | 39% | 33% | 1.1 | 4.0% | +2% | -8% | -12% | -25% | -36% | 30% | 158 |
| 华大基因 300676 | 亏损或困境 | 医疗服务 | — | 136.5 | 5.25 | 1.81 | — | 44% | 50% | 24% | 2.9 | -2.7% | -19% | +8% | -19% | -33% | -44% | 41% | 154 |
| 九洲药业 603456 | 中性 | 医疗服务 | 22.5 | 16.2 | 1.25 | 1.49 | 2.0% | 86% | 35% | 40% | 0.0 | 7.0% | +0% | +36% | -15% | -19% | -44% | 43% | 133 |
| 华厦眼科 301267 | 轻资产现金牛 | 医疗服务 | 28.2 | 24.9 | 1.56 | 2.34 | 1.7% | 43% | 46% | 12% | 1.0 | 5.7% | +9% | -4% | -15% | -29% | -34% | 28% | 127 |
| 成都先导 688222 | 中性 | 医疗服务 | 89.9 | 90.3 | 3.11 | 8.26 | 0.4% | 48% | 49% | 23% | 1.3 | 0.3% | +17% | +92% | +35% | +33% | -43% | 65% | 126 |
| 药康生物 688046 | 中性 | 医疗服务 | 69.0 | 63.1 | 2.34 | 5.56 | 0.7% | 71% | 68% | 21% | 0.8 | 1.8% | +15% | +21% | +102% | +65% | -34% | 63% | 126 |
| 美迪西 688202 | 亏损或困境 | 医疗服务 | — | 149.2 | 1.05 | 6.25 | — | — | 24% | 26% | 4.6 | 0.1% | -11% | +87% | +65% | +42% | -37% | 66% | 125 |
| 金域医学 603882 | 现金流红利 | 医疗服务 | 121.6 | 30.8 | 1.40 | 1.96 | 3.3% | 64% | 36% | 19% | 1.2 | 5.2% | -27% | +7% | -3% | -14% | -39% | 41% | 124 |
| 益诺思 688710 | 中性 | 医疗服务 | 471.2 | 85.2 | 0.83 | 4.75 | — | 25% | 38% | 21% | 1.1 | 1.9% | -2% | +26% | +80% | +89% | -31% | 72% | 112 |
| 迪安诊断 300244 | 成长兑现 | 医疗服务 | 41.8 | 24.5 | 1.07 | 1.71 | 1.9% | 249% | 31% | 8% | 1.6 | 15.8% | -21% | +44% | +15% | +9% | -46% | 64% | 111 |
| 三博脑科 301293 | 中性 | 医疗服务 | 226.4 | 144.2 | 2.36 | 4.50 | — | 23% | 23% | 48% | 2.4 | -1.9% | +17% | +37% | -12% | -16% | -52% | 60% | 107 |
| 博腾股份 300363 | 亏损或困境 | 医疗服务 | — | 210.8 | 0.35 | 2.16 | 0.5% | 75% | 41% | 37% | 1.9 | 6.6% | -21% | +48% | -15% | -20% | -55% | 62% | 107 |
| 药石科技 300725 | 中性 | 医疗服务 | 47.4 | 41.3 | 1.21 | 2.19 | 0.9% | 31% | 42% | 32% | 0.3 | 1.4% | +7% | +16% | +12% | -8% | -34% | 48% | 100 |
| 国际医学 000516 | 重资产陷阱 | 医疗服务 | — | — | — | 2.79 | — | — | 8% | 79% | 7.7 | 11.3% | +14% | -19% | -6% | -26% | -38% | 38% | 91 |
| 创新医疗 002173 | 重资产陷阱 | 医疗服务 | — | — | — | 4.92 | — | — | 7% | 58% | — | -0.7% | +3% | +170% | -14% | -23% | -57% | 66% | 81 |
| 阳光诺和 688621 | 纯久期 | 医疗服务 | 159.4 | 33.7 | 2.25 | 6.59 | 0.3% | 10% | 54% | 6% | 4.0 | -1.1% | +22% | +66% | +14% | -12% | -42% | 52% | 79 |
| 盈康生命 300143 | 亏损或困境 | 医疗服务 | 101.1 | 42.8 | 3.06 | 3.14 | 0.2% | 28% | 26% | 16% | 2.3 | 3.9% | +18% | +7% | +2% | -6% | -36% | 48% | 75 |
| 新里程 002219 | 中性 | 医疗服务 | 240.8 | 91.3 | 2.12 | 3.72 | — | — | 30% | 42% | 4.2 | 0.4% | -1% | -19% | +0% | -7% | -37% | 44% | 74 |
| 诺禾致源 688315 | 中性 | 医疗服务 | 38.4 | — | — | 2.17 | 0.3% | 11% | 43% | 17% | 0.3 | 3.8% | +5% | +7% | +5% | -15% | -30% | 45% | 58 |
| 诚达药业 301201 | 亏损或困境 | 医疗服务 | — | — | — | 2.61 | 0.6% | 34% | 44% | 34% | 0.7 | 0.1% | -0% | +105% | -13% | +10% | -57% | 74% | 55 |
| 诺思格 301333 | 中性 | 医疗服务 | 45.1 | 35.6 | 2.23 | 2.71 | 0.3% | 11% | 37% | 1% | 0.3 | 0.8% | +10% | +20% | -5% | +1% | -51% | 63% | 54 |
| 泓博医药 301230 | 纯久期 | 医疗服务 | 140.0 | — | — | 5.29 | 1.0% | 148% | 31% | 16% | 1.2 | 1.9% | +13% | +19% | +30% | -6% | -55% | 73% | 54 |
| 毕得医药 688073 | 成长兑现 | 医疗服务 | 29.3 | 24.3 | 1.06 | 2.58 | 1.9% | 68% | 44% | 4% | 0.4 | 1.5% | +17% | +27% | -2% | -11% | -44% | 67% | 53 |
| 万邦医药 301520 | 纯久期 | 医疗服务 | 531.3 | — | — | 3.47 | 0.4% | 27% | 49% | 11% | — | -0.6% | +2% | +4% | +98% | +69% | -37% | 80% | 52 |
| 普瑞眼科 301239 | 亏损或困境 | 医疗服务 | 403.7 | 35.7 | 0.46 | 2.37 | — | 22% | 42% | 27% | 3.2 | 7.4% | +18% | -30% | +3% | -24% | -38% | 41% | 51 |
| 博济医药 300404 | 纯久期 | 医疗服务 | 92.0 | — | — | 4.42 | 0.1% | 16% | 33% | 12% | 0.6 | 1.1% | +27% | +7% | +33% | +6% | -36% | 54% | 48 |
| 百诚医药 301096 | 亏损或困境 | 医疗服务 | — | — | — | 1.91 | — | 12% | 66% | 46% | 9.7 | -3.1% | +4% | +51% | -24% | -22% | -48% | 53% | 47 |
| 百花医药 600721 | 纯久期 | 医疗服务 | 153.2 | — | — | 5.73 | 0.3% | 38% | 46% | 13% | — | 0.5% | +4% | +86% | -2% | +28% | -47% | 63% | 46 |
| 睿智医药 300149 | 亏损或困境 | 医疗服务 | — | — | — | 3.54 | — | — | 26% | 16% | 2.7 | 2.2% | -5% | +49% | -7% | -34% | -46% | 63% | 45 |
| ST中珠 600568 | 亏损或困境 | 医疗服务 | — | — | — | 2.71 | — | — | 25% | 14% | — | -0.3% | +4% | +93% | -14% | +14% | -36% | 40% | 43 |
| 和元生物 688238 | 重资产陷阱 | 医疗服务 | — | — | — | 3.22 | — | — | -7% | 65% | — | -4.4% | -3% | +35% | -3% | -24% | -39% | 55% | 42 |
| 兰卫医学 301060 | 亏损或困境 | 医疗服务 | 108.2 | — | — | 2.70 | 1.7% | — | 24% | 18% | 0.6 | 8.0% | -30% | +4% | +15% | +0% | -40% | 53% | 42 |
| 金凯生科 301509 | 现金流红利 | 医疗服务 | 55.8 | — | — | 1.66 | 3.1% | 103% | 42% | 15% | 0.0 | 2.2% | -4% | +34% | -11% | -32% | -43% | 48% | 35 |
| 海特生物 300683 | 亏损或困境 | 医疗服务 | — | — | — | 1.56 | — | — | 43% | 26% | — | -1.9% | -8% | +17% | -10% | -58% | -58% | 62% | 33 |
| 澳洋健康 002172 | 重资产陷阱 | 医疗服务 | 95.1 | — | — | 16.11 | — | — | 14% | 41% | 6.6 | -0.2% | -4% | +27% | +6% | -1% | -40% | 47% | 32 |
| 贝瑞基因 000710 | 亏损或困境 | 医疗服务 | — | — | — | 2.18 | — | — | 45% | 19% | — | -2.1% | -12% | +34% | -22% | -47% | -54% | 48% | 31 |
| 普蕊斯 301257 | 中性 | 医疗服务 | 52.2 | 21.9 | 1.15 | 2.40 | 0.4% | 11% | 26% | 1% | 0.0 | 0.1% | +13% | +94% | -26% | -1% | -55% | 69% | 30 |
| 南模生物 688265 | 亏损或困境 | 医疗服务 | 133.4 | — | — | 1.74 | 0.3% | 30% | 46% | 19% | 0.7 | -0.9% | +12% | +78% | -6% | -36% | -50% | 60% | 30 |
| 南华生物 000504 | 亏损或困境 | 医疗服务 | 69.8 | — | — | 9.84 | — | — | 67% | 18% | 3.2 | -4.8% | +28% | +7% | -10% | -17% | -32% | 40% | 27 |
| 何氏眼科 301103 | 纯久期 | 医疗服务 | 105.7 | — | — | 1.36 | 0.9% | 119% | 40% | 13% | 1.0 | 4.4% | +5% | -2% | -16% | -30% | -38% | 30% | 26 |
| 皓宸医疗 002622 | 亏损或困境 | 医疗服务 | — | — | — | 8.43 | — | — | 47% | 11% | 5.9 | 3.8% | +12% | +8% | -12% | -36% | -54% | 41% | 22 |
| 光正眼科 002524 | 亏损或困境 | 医疗服务 | — | — | — | 18.60 | — | — | 35% | 12% | 5.6 | 5.0% | +5% | +13% | -2% | -12% | -40% | 41% | 21 |
| 数字人 920670 | 亏损或困境 | 医疗服务 | 346.0 | — | — | 6.03 | 0.4% | 65% | 69% | 14% | 0.2 | 1.9% | +12% | +9% | -20% | — | — | — | 14 |
点表头排序。市值单位亿元;去年/YTD 为前复权涨幅;债/EBITDA = 有息负债 ÷ EBITDA。